BioPharma Dive - Latest News

Ono pays $280M to license Ionis rare disease drug

Ionis’ drug, sapablursen, is currently being tested in a Phase 2 trial in patients with polycythemia vera.

Mar 12, 2025 - 16:15
 0
Ono pays $280M to license Ionis rare disease drug

Ionis’ drug, sapablursen, is currently being tested in a Phase 2 trial in patients with polycythemia vera.

Read More

Tags:

Previous Article

Tesla bounces for second day after steepest drop since 2020

Next Article

Human medicines European public assessment report (EPAR): Rekambys, rilpivirine,...

Related Posts

Lilly expands US manufacturing build-out with $50B target

Lilly expands US manufacturing build-out with $50B target

Feb 26, 2025  0

Pfizer taps former Novartis exec to lead cancer drug push

Pfizer taps former Novartis exec to lead cancer drug push

Feb 9, 2025  0

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

Pfizer names Patrizia Cavazzoni, former top FDA officia...

Feb 24, 2025  0